AXSM Axsome Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—
Margins
Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%
Returns
ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $259.69M | $218.38M | $191.20M | $196.00M | $170.99M | $150.04M | $121.46M | $118.77M |
| Cost of revenue | $17.80M | $13.56M | $14.72M | $12.33M | $11.91M | $13.45M | $9.79M | $10.51M |
| Gross profit | $241.89M | $204.81M | $176.48M | $183.67M | $159.08M | $136.59M | $111.67M | $108.25M |
| R&D expense | $50.62M | $46.23M | $52.68M | $48.79M | $40.16M | $49.54M | $44.78M | $55.01M |
| SG&A expense | $203.11M | $208.14M | $185.00M | $169.30M | $150.24M | $130.28M | $120.79M | $113.27M |
| Operating income | -$11.07M | -$49.65M | -$63.36M | -$26.96M | -$46.11M | -$36.71M | -$56.98M | -$72.62M |
| Interest expense | -$3.42M | -$3.20M | $3.09M | -$3.21M | -$3.38M | -$4.09M | $5.26M | -$5.43M |
| Pretax income | -$12.79M | -$51.19M | -$64.54M | -$28.13M | -$47.23M | -$48.93M | -$59.41M | -$74.83M |
| Income tax | $88,000 | $128,000 | $0 | $430,000 | $0 | -$960,000 | $0 | $85,000 |
| Net income | -$12.88M | -$51.31M | -$64.54M | -$28.56M | -$47.23M | -$47.97M | -$59.41M | -$74.91M |
| EBITDA | -$10.94M | -$49.50M | -$63.24M | -$26.84M | -$45.99M | -$36.59M | -$56.83M | -$72.49M |
| EPS (basic) | -0.25 | -0.99 | -1.26 | — | -0.94 | -0.97 | -1.22 | — |
| EPS (diluted) | -0.25 | -0.99 | -1.26 | — | -0.94 | -0.97 | -1.22 | — |
| Weighted avg. shares (diluted) | 52.45M | 51.80M | 51.20M | — | 50.02M | 49.44M | 48.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $313.86M | $319.85M | $305.11M | $322.93M | $325.27M | $303.02M | $300.91M | $315.35M |
| Receivables | $343.11M | $277.46M | $251.06M | $224.46M | $196.51M | $198.82M | $161.40M | $142.00M |
| Inventory | $42.58M | $37.88M | $31.52M | $27.94M | $23.77M | $18.44M | $16.32M | $15.73M |
| Current assets | $724.64M | $656.57M | $611.21M | $588.99M | $565.34M | $536.62M | $494.63M | $485.06M |
| PP&E, net | $943,000 | $874,000 | $567,000 | $562,000 | $605,000 | $667,000 | $773,000 | $584,000 |
| Goodwill | $12.04M | $12.04M | $12.04M | $12.04M | $12.04M | $12.04M | $12.04M | $12.04M |
| Intangibles | $35.75M | $37.36M | $38.95M | $40.52M | $42.13M | $43.73M | $45.32M | $46.89M |
| Total assets | $826.77M | $761.45M | $713.61M | $689.80M | $669.25M | $639.78M | $596.67M | $568.50M |
| Current liabilities | $509.72M | $460.45M | $439.21M | $378.84M | $360.29M | $342.10M | $243.91M | $230.10M |
| Short-term debt | $70.00M | $70.00M | $70.00M | $70.00M | $70.00M | $70.00M | — | $0 |
| Long-term debt | $118.07M | $117.96M | $117.85M | $117.75M | $117.64M | $117.54M | $181.38M | $180.71M |
| Total debt | $188.07M | $187.96M | $187.85M | $187.75M | $187.64M | $187.54M | $181.38M | $180.71M |
| Total liabilities | $721.34M | $678.14M | $659.02M | $601.51M | $595.52M | $566.71M | $543.47M | $511.48M |
| Shareholders' equity | $105.43M | $83.30M | $54.59M | $88.30M | $73.73M | $73.08M | $53.20M | $57.02M |
| Net debt | -$125.79M | -$131.89M | -$117.26M | -$135.19M | -$137.63M | -$115.48M | -$119.53M | -$134.64M |
| Shares outstanding | 52.58M | 52.30M | 51.42M | 50.88M | 50.31M | 49.82M | 49.22M | 48.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.47M | -$32.95M | -$20.70M | -$18.65M | $1.05M | -$32.42M | -$43.38M | -$26.20M |
| Capital expenditure | $197,000 | $450,000 | $121,000 | $71,000 | $58,000 | $13,000 | $338,000 | $30,000 |
| Free cash flow | -$9.67M | -$33.40M | -$20.82M | -$18.72M | $988,000 | -$32.44M | -$43.71M | -$26.23M |
| Investing cash flow | -$197,000 | -$450,000 | -$121,000 | -$71,000 | -$58,000 | -$13,000 | -$338,000 | -$30,000 |
| Financing cash flow | $3.67M | $48.15M | $2.99M | $16.39M | $21.27M | $34.54M | $29.27M | $14.24M |
| Depreciation & amortization | $128,000 | $143,000 | $116,000 | $114,000 | $120,000 | $120,000 | $149,000 | $129,000 |
| Stock-based compensation | $26.36M | $27.15M | $23.44M | $22.73M | $23.10M | $24.61M | $23.31M | $21.99M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.